08:25 EDT eFFECTOR Therapeutics trading halted, news pending
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EFTR:
- Effector Therapeutics’ Stock Issuance Capped: Navigating the Lincoln Park Agreement’s Exchange Limit
- eFfector Therapeutics reports Q4 EPS ($3.42), consensus ($1.65)
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- EFTR Earnings this Week: How Will it Perform?
- eFfector Therapeutics target adjusted to $24 at H.C. Wainwright
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue